Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma
RATIONALE: Sunitinib malate may stop the growth of tumour cells by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the tumour. Giving sunitinib
malate before surgery may make the tumour smaller and reduce the amount of normal tissue that
needs to be removed. Giving sunitinib malate after surgery may kill any tumour cells that
remain after surgery. It is not yet known whether undergoing immediate surgery or surgery
after sunitinib malate is more effective in treating patients with metastatic kidney cancer.
PURPOSE: This randomized phase III trial is studying immediate surgery to see how well it
works compared with surgery after sunitinib malate in treating patients with metastatic
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society